HCWB HCW Biologics Inc.

2.73
-0.09  -3%
Previous Close 2.82
Open 2.77
52 Week Low 2.36
52 Week High 7.775
Market Cap $97,537,746
Shares 35,728,112
Float 17,394,047
Enterprise Value $60,638,502
Volume 66,831
Av. Daily Volume 3,822,479
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
HCW9218
Pancreatic Cancer
Phase 1/2
Phase 1/2
IND cleared by FDA October 28, 2021.

Latest News

  1. MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021.

    "The third quarter of 2021 and recent weeks were an important period for HCW Biologics and our strategy to build a pipeline of first-in-class immunotherapeutic treatments for age-related diseases," stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc. "The third quarter provided bookends to…

    MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021.

    "The third quarter of 2021 and recent weeks were an important period for HCW Biologics and our strategy to build a pipeline of first-in-class immunotherapeutic treatments for age-related diseases," stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc. "The third quarter provided bookends to what has been a busy time for the Company. In July, we closed our initial public offering and subsequently listed our common stock on Nasdaq. The Company has never been on stronger financial footing, and we believe we now have capital resources sufficient to fund our operations into 2023. During the third quarter, we filed our first IND to evaluate our lead bifunctional molecule, HCW9218, in a pancreatic cancer trial.   We completed the regulatory review shortly after the end of the third quarter, and we announced FDA clearance for the Phase 1b clinical trial on October 28, 2021."

    Business Highlights:

    • On July 22, 2021, HCW Biologics closed on its IPO, raising $56 million in gross proceeds. The net proceeds of the offering and the Company's existing cash and cash equivalents are sufficient to fund operating expenses and capital expenditure requirements into 2023.



    • HCW Biologics was added to S&P Total Market Index (TMI) on September 20, 2021.



    • The Company expanded its Board of Directors with the addition of two new independent directors in October 2021, Lisa M. Giles and Gary M. Winer. Ms. Giles has extensive experience in pharmaceutical, diagnostic, device, and other healthcare industries. She held senior leadership positions in strategic planning, operations, and commercial planning. In addition, she brings a wealth of corporate governance experience, having served as a board member for several public companies. Mr. Winer has led and built successful, multinational businesses in the biopharma and diagnostic healthcare sectors as a Chief Executive Officer or President, including senior leadership positions with AbbVie and Abbott. He brings valuable insights and experience for operations as well as support and advice for strategic transactions.



    • On October 28, 2021, HCW Biologics announced that it received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for a Phase 1b first-in-human clinical trial to evaluate HCW9218 in patients with advanced pancreatic cancer. The Company is in discussions with several leading National Cancer Institute-designated cancer centers as potential clinical trial sites. Discussions are simultaneously underway with a research facility to sponsor an IND for a second, investigator-initiated trial to evaluate HCW9218 in patients with solid tumors (breast, ovarian, prostate, and colorectal cancers).



    • HCW Biologics continues IND-enabling studies involving HCW9302, its second lead investigational drug candidate. The Company expects to complete FDA-required preclinical studies in mice by the end of 2021 and non-clinical toxicology studies in non-human primates in the second half of 2022. HCW9302 is an IL-2-based immunotherapeutic designed to stimulate regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and inflammatory factors.   HCW Biologics intends to evaluate HCW9302 in autoimmune diseases.



    • The HCW Biologics' founder and CEO, Dr. Hing C. Wong, has accepted invitations to present at two noted industry events. Dr. Wong will present at the BioFlorida Annual Conference taking place on December 8-10, 2021, in Orlando, Florida, where he will participate in the featured session, "New Strategies in the Fight Against Cancer." Dr. Wong will also lead a presentation during the Cambridge Healthtech Institute's 24th Annual PepTalk taking place on January 17-19, 2022, in San Diego, California. His presentation, entitled "A Novel Platform to Create Multi-functional Immunotherapies for Cancer," will focus on the TOBI™ discovery platform and HCW9218.



    • The Company continues to expand its intellectual property portfolio through filing provisional U.S. applications based upon new research, filing non-U.S. national stage phase patent applications, and filing U.S. trademark applications. As of September 30, 2021, HCW Biologics is the owner of record of 60 pending patent applications worldwide, including 11 pending U.S. utility patent applications, two pending provisional U.S. patent applications, seven pending PCT applications, 36 pending non-U.S. national phase patent applications, and four pending Hong Kong patent applications. The Company also owns five U.S. trademark applications related to its corporate name and logo, and the TOBITM platform.

    Third Quarter Financial Results:

    • Cash and cash equivalents: On September 30, 2021, the Company's cash balance was $15.1 million, short-term investments were $25.0 million and long-term investments were $10.0 million. The net proceeds from the IPO were $49.0 million. The Company estimates that it has sufficient cash to fund operations and capital expenditures into 2023. This estimated cash runway does not include potential sources of non-dilutive financing, which may be obtained from existing or new out-licensing agreements.



    • Research and development (R&D) expenses: R&D expenses were $2.7 million for the three-month period ended September 30, 2021, as compared to $2.1 million for the three-month period ended September 30, 2020. Higher costs in the third quarter of 2021 were primarily the result of higher manufacturing and IND-enabling activity costs. During the nine-month period ended September 30, 2021, R&D expenses were $6.7 million versus $5.8 million during the nine-month period ended September 30, 2020. The 14% increase in expense was driven primarily by an increase in IND-enabling and preclinical activities.



    • General and administrative expenses (G&A): G&A expenses were $1.4 million for the three-month period ended September 30, 2021, as compared to $0.6 million for the three-month period ended September 30, 2020. This reflects an increase in compensation expense including salaries, performance-based bonuses and board compensation, and an increase in certain operating expenses including higher insurance costs, professional fees, and legal services expenses. For the nine-month period ended September 30, 2021, G&A expenses were $3.6 million versus $2.0 million for the same period ended September 30, 2020. The 75% increase was primarily driven by an increase in expenses for salaries, performance-based bonuses, employee benefits, professional fees, and other expenses.



    • Net loss: Net loss was $4.1 million for the three-months ended September 30, 2021, compared to $2.7 million for the three-months ended September 30, 2020. For the nine-months ended September 30, 2021, net loss was $9.7 million, compared to $7.9 million for the same period in the prior year.

    About the TOBI™ platform:

    HCW Biologics has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBI™ discovery platform. The TOBI™ platform is a proprietary immunotherapeutic drug design and discovery platform. The Company has utilized this modular, tunable technology to generate a novel pipeline of immunotherapeutic candidates capable of activating and targeting desired immune responses while blocking unwanted immunosuppressive activities. The balancing of these two activities is believed to be the key to developing immunotherapeutic agents that will be safe, well tolerated and efficacious.

    About HCW Biologics:

    HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation. The Company is developing novel immunotherapies designed to improve health span by disrupting the link between chronic, low-grade inflammation and age-related diseases such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and autoimmune diseases. The Company uses its TOBITM discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. The invention of HCW Biologics' two lead molecules, HCW9218 and HCW9302, was made via the TOBI™ discovery platform. The FDA has cleared HCW Biologics to initiate a first-in-human Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer. HCW9302 is currently undergoing IND-enabling studies for an autoimmune indication.

    Forward Looking Statements:

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words and include, without limitation, statements regarding immunotherapeutic candidates capable of activating and targeting desired immune responses while blocking unwanted immunosuppressive activities; the balancing of certain activities believed to be the key to developing immunotherapeutic agents that are expected to be safe, well tolerated and efficacious; the Company's intention to use TOBI™ technology to develop the next generation of cancer immunotherapeutics; expectations to submit a second IND to the FDA sponsored by a research facility in connection with an investigator-initiated trial to evaluate HCW9218 in solid tumors; sufficient capital resources through 2023; potential clinical trial sites at NCI Cancer Centers; the timing of preclinical and toxicology studies in HCW9302; and the Company's intellectual property applications which are subject to approval. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled "Risk Factors" in the final prospectus related to the Company's initial public offering filed with the Securities and Exchange Commission (the "SEC") on July 21, 2021 and in other filings filed from time to time with the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

    Company Contact:



    Rebecca Byam

    CFO

    HCW Biologics Inc.

    rebeccabyam@hcwbiologics.com
    Investor Relations Contact:



    Maureen McEnroe, CFA

    Executive Vice President

    Tiberend Strategic Advisors, Inc.

    Media Relations Contact:



    Dave Schemelia

    Senior Vice President

    Tiberend Strategic Advisors, Inc.



    Primary Logo

    View Full Article Hide Full Article
  2. Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company's lead product candidate, in refractory, advanced/metastatic pancreatic cancer

    MIRAMAR, Fla., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer. HCW9218 is an injectable, fusion protein complex designed to drive…

    Company cleared to proceed with first-in-human clinical trial to evaluate HCW9218, Company's lead product candidate, in refractory, advanced/metastatic pancreatic cancer

    MIRAMAR, Fla., Oct. 28, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed to evaluate its lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer. HCW9218 is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.

    Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, stated, "The FDA's clearance to proceed with our first-in-human trial for HCW9218 in pancreatic cancer is an important milestone for HCW Biologics and our efforts to advance the development of potentially groundbreaking immunotherapy candidates for cancer and other age-related diseases. Advances in immuno-stimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment. We have created a bifunctional heterodimeric molecule, HCW9218, that can both stimulate the immune system and block the immunosuppressive activity of transforming growth factor-β. In preclinical studies, we showed that HCW9218 enhanced the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel against melanoma and pancreatic cancer, respectively, and simultaneously alleviated the off-target, unwanted effects of chemotherapies on normal tissues. In experimental animal models, HCW9218 was also shown to augment anti-tumor activities of therapeutic and checkpoint antibodies, which are currently standard-of-care anti-cancer treatment for certain solid tumors."

    About Pancreatic Cancer:

    Pancreatic cancer develops when anomalous cells in the pancreas grow and divide out of control to form a tumor. The American Cancer Society estimates that this year in the U.S. alone, there will be 60,430 new pancreatic cancer cases diagnosed, and 48,220 people will die from the disease, making it the third leading cause of cancer-related death behind lung and colon cancers. Most pancreatic cancer patients are diagnosed at stage IV. Because the pancreas lies deep in the abdomen, a physical examination would not detect the presence of a pancreatic tumor. Pancreatic cancer also has no early symptoms, and there are currently no effective screening tests, so the disease is often discovered after the disease has spread to other areas of the body.

    About the TOBI™ platform:

    HCW Biologics has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBI™ discovery platform. The TOBI™ platform is a proprietary immunotherapeutic drug design and discovery platform. The Company has utilized this modular, tunable technology to generate a novel pipeline of immunotherapeutic candidates capable of activating and targeting desired immune responses while blocking unwanted immunosuppressive activities. The balancing of these two activities is believed to be the key to developing immunotherapeutic agents that will be safe, well tolerated and efficacious.

    About HCW Biologics:

    HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation. The Company is developing novel immunotherapies designed to improve health span by disrupting the link between chronic, low-grade inflammation and age-related diseases such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and autoimmune diseases. The Company uses its TOBITM discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. The invention of HCW Biologics' two lead molecules, HCW9218 and HCW9302, was made via the TOBI™ discovery platform. The FDA has cleared HCW Biologics to initiate a first-in-human Phase 1b clinical trial for HCW9218 in patients with advanced pancreatic cancer. HCW9302 is currently undergoing IND-enabling studies for an autoimmune indication.

    Forward Looking Statements:

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words and include, without limitation, statements regarding immunotherapeutic candidates capable of activating and targeting desired immune responses while blocking unwanted immunosuppressive activities; the balancing of certain activities believed to be the key to developing immunotherapeutic agents that are expected to be safe, well tolerated and efficacious; statements regarding the ability of HCW9218 to stimulate the immune system and block the immunosuppressive activity of transforming growth factor-β (TGF-β); and ability of HCW9218 to alleviate the off-target, unwanted effects of chemotherapies on normal tissues and augment anti-tumor activities of therapeutic and checkpoint antibodies. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled "Risk Factors" in the final prospectus related to the Company's initial public offering filed with the Securities and Exchange Commission on July 21, 2021 and Quarterly Report on Form 10-Q filed with the SEC on August 13, 2021. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

    Company Contact:

    Rebecca Byam

    CFO

    HCW Biologics Inc.

    Investor Relations Contact:

    Maureen McEnroe, CFA

    Executive Vice President

    Tiberend Strategic Advisors, Inc.

    Media Relations Contact:

    Dave Schemelia

    Senior Vice President

    Tiberend Strategic Advisors, Inc.



    Primary Logo

    View Full Article Hide Full Article
  3. MIRAMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the appointment of two new independent directors, Lisa M. Giles and Gary M. Winer, to its Board of Directors, effective immediately. The appointments expand the Company's Board to five members, four of whom are independent directors.

    "Adding individuals with Lisa's and Gary's extensive talents and corporate experience in the life sciences industry is an important achievement for our Company and stockholders that we…

    MIRAMAR, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the appointment of two new independent directors, Lisa M. Giles and Gary M. Winer, to its Board of Directors, effective immediately. The appointments expand the Company's Board to five members, four of whom are independent directors.

    "Adding individuals with Lisa's and Gary's extensive talents and corporate experience in the life sciences industry is an important achievement for our Company and stockholders that we believe will contribute greatly to our long-term success," said Hing C. Wong, Ph.D., founder and CEO of HCW Biologics. "Gary and Lisa have long, successful careers building life sciences businesses and serving in senior management roles. On behalf of the Board, I am pleased to welcome them to HCW Biologics and look forward to benefitting from their knowledge and expertise."

    Ms. Giles and Mr. Winer will both serve on the Board's audit committee, chaired by Rick S. Greene, and the Board's compensation committee, chaired by Scott T. Garrett. Dr. Wong will step down from the audit committee but remain a member of the Board of Directors. Mr. Garrett will continue as Chairman of the Board of Directors.

    Ms. Giles commented, "Under Dr. Wong's leadership, HCW stands at the vanguard in the development of a new generation of immunotherapeutics that address the age-related disorders associated with chronic inflammation. The Company's recent initial public offering and the expected advancement of its lead drug candidate, HCW9218, into clinical trials are exciting opportunities for patients and HCW's growth, one that could deliver significant stockholder value. I look forward to working with Dr. Wong, the leadership team and the other Board members as HCW advances its clinical development portfolio."

    Mr. Winer commented, "I am eager to work with Dr. Wong and the other Board members to help HCW Biologics achieve its full potential. As the Company continues to advance the development of its lead drug candidates, HCW9218 and HCW9302, I expect stockholders and patients to have the opportunity to benefit from important therapeutic advancements that could change the treatment of age-related disorders. I look forward to providing guidance to the Company based on my experience working with multinational pharmaceutical companies if and when the Company is ready to strike strategic collaborations and co-development deals."

    About Lisa M. Giles:

    Lisa M. Giles founded Giles & Associates Consultancy, Inc. (GAC) to serve the life sciences industry and academic medical centers since 2000. She is the firm's Managing Director and Chief Executive Officer. Her career has spanned more than 35 years in the pharmaceutical, diagnostic, medical device, and healthcare industries and included extensive experience in enterprise strategic planning, and R&D and commercial planning. Ms. Giles has also served on the Boards of Directors of several public companies. She currently serves as an independent director on the Board of Directors for Milestone Pharmaceuticals (MIST) and the Northwestern Memorial Health System Foundation Board. Previously, she served on the Boards of Directors for GenMark Diagnostics (GNMK) from 2015 to 2021; Durata Therapeutics, Inc. from 2012 to 2014; and Intranasal Therapeutics, Inc. from 2005 to 2006. Ms. Giles also founded Optivara, Inc., a sister company to GAC, and served as Chief Executive Officer from 2013 to 2019. Prior to founding GAC, Ms. Giles held the position of Vice President of Strategy Development for G.D. Searle Pharmaceuticals, a division of Monsanto, and served in various leadership roles with Abbott Laboratories. Ms. Giles received a B.S. from Juniata College and completed executive management programs at Stanford University and the University of Chicago.

    About Gary M. Winer:

    As a consultant at DRC Health Care Advisors since 2015, Gary M. Winer has advised biopharmaceutical, medical device, and diagnostic companies on business strategy, product and portfolio planning and commercialization in international markets. Previously, he served as President and Chief Executive Officer of ORGENTEC Diagnostika GmbH, a private equity-owned specialty manufacturer of autoimmune and infectious disease diagnostic tests, from April 2019 until the sale of the company in September 2021 to Sebia. Mr. Winer held a number of senior leadership positions at Abbott and the company's biotechnology spinoff, AbbVie, from 2003 to 2014. Most recently, he served as Vice President of Global Commercial Strategies at AbbVie (April 2014 to January 2015) and President and Chief Executive Officer of AbbVie Japan (January 2013 to April 2014). Before AbbVie's separation from Abbott, Mr. Winer served as Divisional Vice President for the company's Latin America and Canadian diagnostic business unit, Divisional Vice President for U.S. Commercial Operations, and Corporate Vice President and President at Abbott Japan. Mr. Winer currently serves on the Boards of Directors of Lensar, Inc. and other private healthcare companies. Mr. Winer received a B.S. in Finance from California State University and earned an M.B.A. from Kellogg Graduate School of Management at Northwestern University.

    About the TOBI™ platform:

    HCW Biologics has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBI™ discovery platform. The TOBI™ platform is a proprietary immunotherapeutic drug design and discovery platform. HCW has utilized this modular, tunable technology to generate a novel pipeline of immunotherapeutic candidates capable of activating and targeting desired immune responses while blocking unwanted immunosuppressive activities. The balancing of these two activities is believed to be the key to developing immunotherapeutic agents that will be safe, well tolerated and efficacious.

    About HCW Biologics:

    HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation. The Company is developing novel immunotherapies designed to improve health by disrupting the link between chronic, low-grade inflammation and age-related diseases such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and autoimmune diseases. HCW uses its TOBI™ discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. Two of HCW Biologics lead inventions via the TOBI™ platform include molecules HCW9218 and HCW9302, both currently undergoing IND-enabling studies.

    Forward Looking Statements:

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words and include, without limitation, statements regarding immunotherapeutic candidates capable of activating and targeting desired immune responses while blocking unwanted immunosuppressive activities; expected advancement of the Company's lead drug candidate HCW9218 into clinical trials and the anticipated related delivery of significant near-term and longer-range shareholder value; the opportunity to benefit from important therapeutic advancements that could change the treatment of age-related disorders; and the Company potentially entering into strategic collaborations and co-development deals to further its clinical development. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled "Risk Factors" in the final prospectus related to the Company's initial public offering filed with the Securities and Exchange Commission (the "SEC") on July 21, 2021 and Quarterly Report on Form 10-Q filed with the SEC on August 13, 2021. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

    Company Contact:

    Rebecca Byam

    CFO

    HCW Biologics Inc.

    Investor Relations Contact:

    Maureen McEnroe, CFA

    Executive Vice President

    Tiberend Strategic Advisors, Inc.

    Media Relations Contact:

    Dave Schemelia

    Senior Vice President

    Tiberend Strategic Advisors, Inc.



    Primary Logo

    View Full Article Hide Full Article
View All HCW Biologics Inc. News